Document Detail


Spotlight on rasagiline in Parkinson's disease.
MedLine Citation:
PMID:  18072817     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Rasagiline (Azilect) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). It is administered orally once daily and is approved in the US, Canada, Mexico, Israel and the EU for use as monotherapy and as adjunct therapy in the treatment of Parkinson's disease. Results of well designed clinical studies indicate that rasagiline is effective as initial monotherapy and improves Parkinson's symptomatology in patients with early Parkinson's disease. In addition, when administered in conjunction with levodopa, in patients with moderate to advanced disease and motor fluctuations, rasagiline reduces mean daily 'off' time and increases daily 'on' time without troublesome dyskinesias, compared with controls. Rasagiline is generally well tolerated as monotherapy and adjunctive therapy and is administered once daily. Thus, rasagiline, administered as a simple and convenient dosage regimen, is a well tolerated and effective option for monotherapy in patients with early Parkinson's disease and for adjunctive therapy in patients with moderate to advanced disease.
Authors:
Vicki Oldfield; Gillian M Keating; Caroline M Perry
Related Documents :
16222437 - Optimising levodopa therapy for the management of parkinson's disease.
7823067 - Which factors predict cognitive decline in parkinson's disease?
12185157 - Effects of deep brain stimulation and levodopa on postural sway in parkinson's disease.
19557097 - Update on ropinirole in the treatment of parkinson's disease.
1700517 - The use of molecular techniques in studying viral pathogenesis in the nervous system.
22907037 - Magnesium: novel applications in cardiovascular disease - a review of the literature.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  CNS drugs     Volume:  22     ISSN:  1172-7047     ISO Abbreviation:  CNS Drugs     Publication Date:  2008  
Date Detail:
Created Date:  2007-12-12     Completed Date:  2008-02-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9431220     Medline TA:  CNS Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  83-6     Citation Subset:  -    
Affiliation:
Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections
Republished from:
Drugs. 2007;67(12):1725-47   [PMID:  17683172 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: ...
Next Document:  Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional s...